Clinical Trial Detail

NCT ID NCT03780517
Title Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boston Pharmaceuticals
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

thyroid gland medullary carcinoma

Therapies

DS-5010

Age Groups: senior adult

Additional content available in CKB BOOST